Fintepla Access Challenges: What Providers and Prescribers Need to Know in 2026

Fintepla (fenfluramine) is not in a traditional drug shortage — but the access ecosystem surrounding this medication is complex enough that many patients face delays of weeks to months before receiving their first dose. As a clinician prescribing Fintepla for Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS), understanding the end-to-end access pathway is essential for managing patient expectations and minimizing gaps in care.

Clinical Indications and Current Approval Status

Fintepla (fenfluramine) is FDA-approved as add-on therapy for:

Seizures associated with Dravet syndrome (DS) in patients ≥2 years (approved June 2020)

Seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years (approved March 2022)

Fintepla is a Schedule IV controlled substance (CIV). Treatment guidelines from the Dravet Syndrome Foundation and international consensus position fenfluramine as a second-line add-on for DS (after valproate) and as an add-on option for LGS.

FINTEPLA REMS: What Every Prescriber Must Know

FINTEPLA is available only through the FINTEPLA REMS (Risk Evaluation and Mitigation Strategy) program. As a prescriber, you must:

1. Enroll as a certified prescriber in the FINTEPLA REMS program at FinteplaREMS.com or 1-877-964-3649.

2. Obtain a baseline echocardiogram to evaluate for valvular heart disease (VHD) and pulmonary arterial hypertension (PAH) before initiating treatment.

3. Repeat echocardiograms every 6 months during treatment and once at 3-6 months post-discontinuation.

4. Enroll patients in the REMS program and direct prescriptions to REMS-certified specialty pharmacies only.

Echocardiogram criteria requiring reassessment: presence of VHD (mild or greater aortic regurgitation, or moderate or greater mitral regurgitation with additional VHD characteristics), or PAH (PASP >35 mm Hg). In clinical trials for DS and LGS lasting up to 3 years, no patient developed VHD or PAH. The 2025 long-term extension study confirmed these findings, with the most common adverse events being pyrexia, nasopharyngitis, and decreased appetite.

Key Dosing and Drug Interaction Points for Prescribers

Fintepla is available as a 2.2 mg/mL oral solution. Dosing is weight-based:

Starting dose: 0.1 mg/kg twice daily; titrate weekly as tolerated

Maximum without stiripentol: 0.35 mg/kg twice daily (maximum 26 mg/day)

Maximum with stiripentol + clobazam: 0.2 mg/kg twice daily (maximum 17 mg/day)

With strong CYP1A2 or CYP2D6 inhibitors: maximum 20 mg/day

Critical drug interactions to flag: Fintepla is contraindicated with MAOIs (do not use within 14 days). Use caution with SSRIs, SNRIs, and TCAs due to risk of serotonin syndrome. Strong CYP1A2, CYP2B6, or CYP3A inducers (e.g., rifampin, St. John's Wort) will decrease fenfluramine plasma levels; strong CYP1A2 or CYP2D6 inhibitors (e.g., fluvoxamine, paroxetine) will increase them. Avoid use in patients with moderate-to-severe renal impairment or hepatic impairment.

Navigating Prior Authorization for Fintepla

Insurance prior authorization is required by most payers before they will cover Fintepla. A well-documented PA request should include:

Confirmed diagnosis (genetic testing for SCN1A mutation in DS; EEG findings for LGS)

Seizure frequency log (type, frequency, duration) demonstrating inadequate control

Prior AED history: agents tried, doses, duration, reason for discontinuation

Clinical rationale referencing FDA-approved labeling

REMS compliance plan (baseline echocardiogram scheduled or completed)

Standard PA review takes 30-45 days; expedited review for urgent cases may be completed in 72 hours. Initial denials can frequently be overturned on appeal with comprehensive documentation. UCB's ONWARD program (1-833-463-7547) can provide PA support.

Helping Patients Navigate Specialty Pharmacy and Affordability

Prescriptions for Fintepla must be directed to REMS-certified specialty pharmacies. Standard retail pharmacies cannot dispense it. When enrolling a patient, direct them to the FINTEPLA REMS program to identify a nearby certified pharmacy, or contact UCB's ONWARD program to coordinate.

Financial assistance options to inform patients about:

ONWARD Copay Assistance Program: Commercially insured patients pay no more than $25/month; many pay $0. Also covers echocardiogram costs.

Medicaid: Average out-of-pocket cost of $4.95-$9.85/month for most Medicaid patients.

Patient assistance: Uninsured or underinsured patients can contact UCB's patient assistance program for additional support.

Using medfinder to Help Patients Find Pharmacies

For patients struggling to locate a certified specialty pharmacy, medfinder for providers is a service that contacts pharmacies on patients' behalf to identify which REMS-certified locations can fill their Fintepla prescription. This reduces administrative burden on your staff while ensuring patients receive care promptly. See the provider guide for helping patients find Fintepla.